US sweet protein startup Oobli has raised $18M and partnered with global ingredients giant Ingredion to develop ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...

Study results indicated that controlling diabetes with insulin helps to prevent the emergence of antibiotic-resistant S. aureus.

People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With ...

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.